Moderna Inc (MRNA)vsNkarta Inc (NKTX)
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
NKTX
Nkarta Inc
$2.75
+4.56%
HEALTHCARE · Cap: $190.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 578701199% more annual revenue ($2.23B vs $385). NKTX leads profitability with a 0.0% profit margin vs -141.4%. NKTX earns a higher WallStSmart Score of 32/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NKTX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Intrinsic value data unavailable for NKTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NKTX
The strongest argument for NKTX centers on Price/Book, Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NKTX
The primary concerns for NKTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NKTX is a value play — different risk/reward profiles.
NKTX carries more volatility with a beta of 0.94 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NKTX generates stronger free cash flow (-24M), providing more financial flexibility.
Bottom Line
NKTX scores higher overall (32/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nkarta Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?